CHAARTED metastatic prostate cancer QoL findings favor docetaxel
medwireNews: In men with metastatic hormone-sensitive prostate cancer, the addition of docetaxel to androgen deprivation therapy (ADT) leads to an initial dip in quality of life (QoL), with a subsequent benefit over time, show CHAARTED results published in the Journal of Clinical Oncology.
At the 3-month mark, the decline from baseline in the mean Functional Assessment of Cancer Therapy-Prostate (FACT-P) score was statistically significant for the 397 patients who were randomly assigned to receive six cycles of docetaxel 75 mg/m2 every 3 weeks alongside ADT, but not for their 393 counterparts given ADT alone.
By 12 months, the average FACT-P score was comparable to baseline for the docetaxel group, but had decreased significantly for the ADT alone group.
Docetaxel-treated patients reported significantly worse fatigue, but only at the 3-month assessment, while pain intensity and interference were comparable between groups at all timepoints, report Alicia Morgans (Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA) and team.
They stress that these results “must be considered in the context of the population assessed” and in light of a recent updated analysis that failed to find a survival benefit with chemohormonal therapy in men with low-volume disease.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group